We're unable to sign you in at this time. Please try again in a few minutes.
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Article |

Phenylbutazone Leukopenia

AMA Arch Intern Med. 1959;103(6):957-961. doi:10.1001/archinte.1959.00270060109014.
Text Size: A A A
Published online


While effective in a variety of rheumatic conditions, phenylbutazone has incurred the reputation of being a relatively toxic drug. Purpura,1 depression of erythropoiesis,2 aggravation of bleeding ulcers,1 and Stevens-Johnson syndrome3 have been reported consequent to its administration, but by far the most alarming complications of phenylbutazone therapy have been agranulocytosis and, more frequently, leukopenia.1 The nature of white cell damage produce by this agent has not been previously elucidated, although structural similarities to aminopyrine have caused speculation as to analogous leukotoxicity.

Certain drugs, when added to the serum of patients with leukopenia, will cause agglutination of autologous and homologous white blood cells. Gold and aminopyrine particularly have been mentioned in this regard.4 It is the purpose of this communication to add phenylbutazone to this list and to examine the relationship that the drug bears to aminopyrine in leukoagglutination activity. We have studied a patient whose serum caused agglutination of homologous


Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

First Page Preview

View Large
First page PDF preview





Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Please click the checkbox indicating that you have read the full article in order to submit your answers.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.


Some tools below are only available to our subscribers or users with an online account.

13 Citations

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

Related Content

Customize your page view by dragging & repositioning the boxes below.